Fimasartan Potassium Trihydrate/Hydrochlorothiazide

非马沙坦钾三水合物/氢氯噻嗪

Report date: 2026/02/04 14:50:53

Base Information

Drug NameFimasartan Potassium Trihydrate/Hydrochlorothiazide
Drug Alias Name非马沙坦钾/氢氯噻嗪Fimasartan Potassium/HydrochlorothiazideHydrochlorothiazide/Fimasartan Potassium氢氯噻嗪/非马沙坦钾氢氯噻嗪非马沙坦钾 +[10] 
ClassificationSmall molecules
Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsAngiotensin II Receptor Type 1 antagonists
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin II Receptor Type 1
Therapy Area/IndicationsEssential Hypertension
Global Approved IndicationsEssential Hypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2013/06/28
Country/TerritorySouth Korea
CombinationsYes HydrochlorothiazideFimasartan Potassium Trihydrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBoryung Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDong Wha Pharm Co Ltd
Inactive CompaniesN/A
Active IndicationsEssential Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A